RP-3500 is a highly selective ATRi withclinical activity demonstrated in phase I/II TRESR study (NCT04497116) across aspectrum of tumor types and genomic alterations in DDR genes, includingPARPi-resistant EOC with BRCA1 or RAD51Cmutations.90 Interestingly, the objective response rate (ORR) was25% (5/20) among patients with EOC, 17 of whom presented with platinum-resistantdisease and 18 of whom had prior PARPi treatment. Here, BRCA1 is linked to neoplasm.